Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations

Tamra Lysaght; Ian Kerridge; Douglas Sipp; Gerard Porter; Benjamin J. Capps

doi:10.1016/j.stem.2013.11.013

Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations

Tamra Lysaght, Ian Kerridge, Douglas Sipp, Gerard Porter, Benjamin J. Capps

Résultat de recherche: Comment/debate › examen par les pairs

20 Citations (Scopus)

Résumé

Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.

Langue d'origine	English
Pages (de-à)	647-651
Nombre de pages	5
Journal	Cell Stem Cell
Volume	13
Numéro de publication	6
DOI	https://doi.org/10.1016/j.stem.2013.11.013
Statut de publication	Published - déc. 5 2013
Publié à l'externe	Oui

Note bibliographique

Funding Information:
The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).

ASJC Scopus Subject Areas

Molecular Medicine
Genetics
Cell Biology

Accès au document

10.1016/j.stem.2013.11.013

Autres fichiers et liens

Citer

@article{425732536ed94932aa9ca4a540d8ca9a,

title = "Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations",

abstract = "Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.",

author = "Tamra Lysaght and Ian Kerridge and Douglas Sipp and Gerard Porter and Capps, {Benjamin J.}",

note = "Funding Information: The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).",

year = "2013",

month = dec,

day = "5",

doi = "10.1016/j.stem.2013.11.013",

language = "English",

volume = "13",

pages = "647--651",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Oversight for clinical uses of autologous adult stem cells

T2 - Lessons from international regulations

AU - Lysaght, Tamra

AU - Kerridge, Ian

AU - Sipp, Douglas

AU - Porter, Gerard

AU - Capps, Benjamin J.

N1 - Funding Information: The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).

PY - 2013/12/5

Y1 - 2013/12/5

N2 - Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.

AB - Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.

UR - http://www.scopus.com/inward/record.url?scp=84890065690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890065690&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2013.11.013

DO - 10.1016/j.stem.2013.11.013

M3 - Comment/debate

C2 - 24315438

AN - SCOPUS:84890065690

SN - 1934-5909

VL - 13

SP - 647

EP - 651

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 6

ER -

Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations

Résumé

Note bibliographique

ASJC Scopus Subject Areas

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer